Financing and going-concern risk
The company expects continued losses and needs external capital to operate.
- Scope
- Corporate continuity and pipeline funding
- Materiality
- high
SAB Biotherapeutics, Inc.
SAB Biotherapeutics, Inc. is a U.S.-based clinical-stage biopharmaceutical company developing human immunoglobulin G (hIgG) therapies for immune and autoimmune disorders. Its platform uses transchromosomic bovine technology to generate disease-targeted polyclonal antibodies, with lead development centered on SAB-142 for autoimmune type 1 diabetes.
−100,0 %
9.46
9.46
| % | |
|---|---|
| Lead clinical candidate | 0% SAB-142 and related development programs targeting autoimmune type 1 diabetes. |
| Immunotherapy pipeline | 0% Other hIgG product candidates for immune and autoimmune disorders. |
| Tc-Bovine antibody platform | 0% Proprietary transchromosomic cattle platform used to produce disease-targeted hIgG. |
| Government-funded countermeasure work | 100% Research and development supported by U.S. government programs and contracts. |
SAB Biotherapeutics primarily serves government agencies, clinical investigators, and future commercial patients...
- Government funding agenciesprimary
U.S. agencies and programs that fund development, countermeasure, and rapid-response work.
- Clinical development ecosystemprimary
Trial sites, investigators, CROs, and collaborators supporting SAB-142 and other studies.
- Future autoimmune patientsprimary
Patients with type 1 diabetes and other autoimmune disorders who would use approved therapies.
- Commercial partnerssecondary
Potential partners for sales, marketing, and distribution if products reach approval.
The company is headquartered in the United States and conducts its core development and corporate activities from there...
- •United States is the core operating and funding base
- •FDA is the primary regulatory pathway for lead programs
- •UK MHRA and Australian TGA are additional development markets
- •Specialty animal facilities support Tc-Bovine plasma production
- •A second facility is being established for redundancy and scale
SAB Biotherapeutics is focused on advancing its lead hIgG programs through clinical development and building the...
01
Advance SAB-142 clinical developmentshort-term
The lead candidate is the main value driver and proof point for the platform.
02
Expand platform into additional autoimmune indicationsmedium-term
A broader indication set can increase the addressable market for the hIgG platform.
03
Increase manufacturing resilience and scalemedium-term
Animal-based plasma production requires capacity, redundancy, and operational control.
04
Prepare for commercialization pathwaysmedium-term
Approval alone is not sufficient without sales, marketing, and distribution execution.
The company faces the typical risks of a clinical-stage biotech: clinical failure, regulatory delay, and the need for...
Clinical development failure
The company depends on proving SAB-142 and other candidates in human studies.
- Scope
- Lead candidate and pipeline value
- Materiality
- high
Regulatory approval risk
Product candidates must satisfy FDA and other regulators before commercialization.
- Scope
- SAB-142 and future autoimmune indications
- Materiality
- high
Manufacturing and facility dependence
Tc-Bovine plasma production requires specialized animal facilities and redundancy.
- Scope
- Supply continuity and scale-up
- Materiality
- medium
Third-party collaboration and data integrity risk
R&D and clinical work rely on CROs, contractors, and external scientific data.
- Scope
- Trial execution and decision-making
- Materiality
- medium
Government grant revenue recognition
Affects reported revenue and comparability across periods
Clinical trial and R&D accruals
Affects operating expense timing
Valuation allowance on deferred tax assets
Affects tax provision and equity
Going-concern assessment
Affects liquidity disclosure and investor interpretation
Apogee Therapeutics, Inc.
APGE · Biological Products, (No Diagnostic Substances)
Sana Biotechnology, Inc.
SANA · Biological Products, (No Diagnostic Substances)
VERU INC.
VERU · Pharmaceutical Preparations
Jade Biosciences, Inc.
JBIO · Pharmaceutical Preparations
Atara Biotherapeutics, Inc.
ATRA · Biological Products, (No Diagnostic Substances)
Atara Biotherapeutics is a U.S.-based biotechnology company focused on T-cell immunotherapy built around its allogeneic Epstein-Barr virus (EBV) T-cell platform.
Cabaletta Bio, Inc.
CABA · Biological Products, (No Diagnostic Substances)
: 29/04/2026